Literature DB >> 9260590

Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma.

J L Xia1, B H Yang, Z Y Tang, F X Sun, Q Xue, D M Gao.   

Abstract

The antitumor and anti-metastatic effects of a potent angiogenesis inhibitor, O-(chloroacetyl-carbamoyl)fumagillol (TNP-470), was investigated in a highly metastatic model of human hepatocellular carcinoma-LCI-D20. Small pieces of LCI-D20 tumor tissue were implanted subcutaneously into the right axillary region of 24 nude mice; the mice were then randomized into two groups. To one group, TNP-470 30 mg/kg was given as a subcutaneous injection every other day from day 1 to day 15 and the mice were sacrificed on day 26. An antitumor effect of TNP-470 was clearly demonstrated by tumor weight (0.97 +/- 0.34 g compared to 2.04 +/- 0.34 g, P < 0.001) and alpha-Fetoprotein value (93 +/- 59 micrograms/L compared to 769 +/- 282 micrograms/L, P < 0.001). There was also an anti-metastatic effect of TNP-470. Lung metastases developed in only 1 of 12 mice in the treated group, while they developed in 6 of mice of the control group. No severe side-effect of TNP-470 was found in this study. In vitro study revealed that the purified hepatoma cells were insensitive to TNP-470 (the 50% inhibitory concentration was 43 micrograms/ml). These results suggest that the angiogenesis inhibitor TNP-470 has both strong antitumor and anti-metastatic effects on a human hepatocellular carcinoma model in nude mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9260590     DOI: 10.1007/bf01240121

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  20 in total

1.  Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent.

Authors:  M Kusaka; K Sudo; T Fujita; S Marui; F Itoh; D Ingber; J Folkman
Journal:  Biochem Biophys Res Commun       Date:  1991-02-14       Impact factor: 3.575

2.  Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation.

Authors:  L A Liotta; J Kleinerman; G M Saidel
Journal:  Cancer Res       Date:  1974-05       Impact factor: 12.701

3.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth.

Authors:  D Ingber; T Fujita; S Kishimoto; K Sudo; T Kanamaru; H Brem; J Folkman
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

4.  Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470).

Authors:  M Yamaoka; T Yamamoto; T Masaki; S Ikeyama; K Sudo; T Fujita
Journal:  Cancer Res       Date:  1993-09-15       Impact factor: 12.701

5.  Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines.

Authors:  M Yamaoka; T Yamamoto; S Ikeyama; K Sudo; T Fujita
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

6.  Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules.

Authors:  H F Dvorak; J A Nagy; J T Dvorak; A M Dvorak
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

Review 7.  Clinical trials of antiangiogenic agents.

Authors:  M J Hawkins
Journal:  Curr Opin Oncol       Date:  1995-01       Impact factor: 3.645

8.  Antitumour effect of a synthetic analogue of fumagillin on murine renal carcinoma.

Authors:  T Morita; N Shinohara; A Tokue
Journal:  Br J Urol       Date:  1994-10

9.  Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.

Authors:  T Kato; K Sato; H Kakinuma; Y Matsuda
Journal:  Cancer Res       Date:  1994-10-01       Impact factor: 12.701

10.  Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay.

Authors:  H Yamaue; H Tanimura; K Noguchi; T Hotta; M Tani; T Tsunoda; M Iwahashi; M Tamai; S Iwakura
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

View more
  7 in total

Review 1.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 2.  Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential.

Authors:  Z Y Tang; F X Sun; J Tian; S L Ye; Y K Liu; K D Liu; Q Xue; J Chen; J L Xia; L X Qin; S L Sun; L Wang; J Zhou; Y Li; Z C Ma; X D Zhou; Z Q Wu; Z Y Lin; B H Yang
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 3.  Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma.

Authors:  R Tung-Ping Poon; S T Fan; J Wong
Journal:  Ann Surg       Date:  2000-07       Impact factor: 12.969

4.  Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study.

Authors:  R T Poon; I O Ng; C Lau; L X Zhu; W C Yu; C M Lo; S T Fan; J Wong
Journal:  Ann Surg       Date:  2001-02       Impact factor: 12.969

Review 5.  A decade's studies on metastasis of hepatocellular carcinoma.

Authors:  Zhao-You Tang; Sheng-Long Ye; Yin-Kun Liu; Lun-Xiu Qin; Hui-Chuan Sun; Qin-Hai Ye; Lu Wang; Jian Zhou; Shuang-Jian Qiu; Yan Li; Xue-Ning Ji; Hu Liu; Jing-Ling Xia; Zhi-Quan Wu; Jia Fan; Zeng-Chen Ma; Xin-Da Zhou; Zhi-Ying Lin; Kang-Da Liu
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-18       Impact factor: 4.553

Review 6.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

Review 7.  Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives.

Authors:  Hui-Chuan Sun; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-03-18       Impact factor: 4.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.